Faculty Profiles - NAKAMURA Keiichiro

Papers - NAKAMURA Keiichiro

Division display 201 - 205 of about 205 ／ All the affair displays >>

Secretory leukoprotease inhibitor inhibits cell growth through apoptotic pathway on ovarian cancer

Keiichiro Nakamura, Norio Takamoto, Atsushi Hongo, Junichi Kodama, Fernando Abrzua, Yasutomo Nasu, Hiromi Kumon, Yuji Hiramatsu

ONCOLOGY REPORTS 19 ( 5 ) 1085 - 1091 2008.5

Language：English Publishing type：Research paper (scientific journal) Publisher：SPANDIDOS PUBL LTD

In light of the poor prognosis for ovarian cancer, research continues for innovative and efficacious treatment modalities. It is now widely accepted that new approaches for the treatment of ovarian cancers are pivotal in further improving prognosis of this disease. Secretory leukoprotease inhibitor (SLPI) is an 11.7-kDa non-glycosylated, serine protease inhibitor that has a broad inhibitory spectrum against serine protease. SLPI showed potential therapeutic inhibitory effects mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), TNF-alpha, death receptor (DR)-4, DR-5 and TNF receptor (TNFR)-I expression which lead to an activation of apoptosis pathway through Caspase-2, Caspase-8 and Caspase-9. We examined whether levels of SLPI protein expression correlated with clinicopathological characteristics in 58 ovarian cancer samples, and investigated the role of SLPI and its biological functions. SLPI expression showed a significant correlation between low expression of SLPI and amount of ascites (p=0.021), lymph node metastasis (p=0.011). We propose that SLPI could be considered a therapeutic target for the treatment of ovarian cancer.

Web of Science

researchmap

Expression of the serine protease hepsin and clinical outcome of human endometrial cancer

Tamaki Matsuo, Keiichiro Nakamura, Norio Takamoto, Junichi Kodama, Atsushi Hongo, Fernando Abrzua, Yasutomo Nasu, Hiromi Kumon, Yuji Hiramatsu

Anticancer Research 28 ( 1 A ) 159 - 164 2008.1

Language：English Publishing type：Research paper (scientific journal)

Background: Hepsin is a type II transmembrane serine protease originally identified in the human liver as a cDNA clone. Hepsin was found to be significantly overexpressed in cancer samples compared to matched various tissues (e.g. prostate, renal, ovarian carcinoma). The purpose of the present study was to examine hepsin expression and to evaluate its clinicopathological significance in endometrial cancer. Patients and Methods: Hepsin expression was examined by immunohistochemisty in 34 cases with normal endometrium as a control, 11 cases with endometrial hyperplasia, and 128 cases with endometrioid adenocarcinoma. Results: Hepsin expression was found to be significantly higher in endometrial cancer compared to normal endometrium and endometrial hyperplasia. High levels of hepsin expression were associated with advanced stage (p&lt
0.001), high grade (p=0.002), depth of myometrial invasion (p&lt
0.001), cervical involvement (p=0.007), lymph node metastasis (p=0.001), lymph vascular space (LVS) involvement (p=0.006), ovarian metastasis (p=0.002), and peritoneal cytology (p=0.03) of endometrial cancer. Conclusion: These findings indicate that hepsin protein expression could be an important indication for high risk of endometrial cancer.

Scopus

PubMed

researchmap

外陰Merkel Cell Carcinomaの一症例

豊嶋英理子, 関典子, 中村圭一郎, 本郷淳司, 児玉順一, 平松祐司, 柳井広之, 河本義之, 藤原道久, 高尾彰, 物部泰昌

日本臨床細胞学会岡山支部会誌 26 13 - 14 2007.12

単発性肝転移再発を来たした子宮頸部小細胞癌の2症例

豊嶋英理子, 本郷淳司, 関典子, 中村圭一郎, 児玉順一, 平松祐司

現代産婦人科 56 ( 2 ) 59 - 59 2007.9

Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines

Keiichiro Nakamura, Yasutomo Nasu, Atsushi Hongo, Tamaki Matsuo, Junichi Kodama, Shin Ebara, Atsushi Nagai, Fernando Abrzua, Hiromi Kumon, Yuji Hiramatsu

International Journal of Oncology 28 ( 2 ) 393 - 398 2006

Language：English Publishing type：Research paper (scientific journal) Publisher：Spandidos Publications

In light of the poor prognosis for ovarian cancer patients, the research continues for innovative and efficacious treatment modalities. Along with surgical and chemotherapeutic regimens, gene therapy has emerged as one of the leading contenders in the treatment armamentarium. Hepsin is a type II transmembrane serine protease originally identified in the human liver as a cDNA clone. However, the biological function of Hepsin expression remains unclear. Apoptotic cell was increasingly common among higher proportions of Hepsin transfectants. We discovered that first-time stable transfectants of Hepsin significantly inhibited cell growth in the monolayer, anchorage-independent cell growth in the soft agar in vitro, and tumorigenicity in vivo in ovarian cancer cell lines. These results demonstrated that Hepsin has a potential therapeutic effect that inhibits through up-regulation of p53-dependent apoptosis and caspase-3, -6, and -7 activations. Our findings in this study identify Hepsin as a target for new approaches in ovarian cancer treatment.

DOI： 10.3892/ijo.28.2.393

Scopus

PubMed

researchmap

　 PREV - NEXT 　

< NAKAMURA Keiichiro >

Papers - NAKAMURA Keiichiro